Biomed Industries, Inc. develops innovative treatments for unmet needs by treating neurological diseases, metabolic and cardiovascular disorders: ALS, Alzheimer's disease, Huntington's Disease, Traumatic Brain Injury, Major Depressive Disorder, Stroke, Diabetes, Obesity, Alcohol Use Disorder, Liver Disease MASH and Rett Syndrome
Mentions in press and media 18
| Date | Title | Description |
| 23.06.2025 | Biomed Industries Presents Breakthrough Phase 2 Results of NA-931, an Oral Quadruple Agonist for Obesity , at ADA 2025 | Biomed Industries, Inc- logo Biomed pipeline NA-931 for weight loss Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 NA-931's Phase 2... |
| 17.06.2025 | Biomed Industries, Inc. to Present Phase 2 Results of Oral Obesity Drug NA-931 and Host Press Conference at ADA 2025 | Biomed Industries, Inc- logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. to Present Phase 2 Results of NA-931, a First-in-Class Oral Therapy for Obesity, and Host a Press Conference at the ADA 025 Phase 2 results confirm ... |
| 11.06.2025 | Biomed Industries, Inc. to Unveil Unified Acceleration Platform at ADA 2025, Linking Alzheimer’s, Obesity, and Diabetes | Biomed Industries, Inc- logo NA-931 for weight loss NA-831 for Alzheimer's Disease Biomed Industries, Inc. to Unveil Unified Acceleration Platform at American Diabetes Association (ADA) 2025, Linking Alzheimer’s, Obesity, and Diabetes By li... |
| 05.05.2025 | Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025 | Biomed Industries, Inc. logo Biomed pipeline NA-931 for weight loss Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Medicine Alternative to Injectables for Obesity—at ADA Conference 2025 in Chicago We believe the future... |
| 31.03.2025 | Biomed Industries CEO to Chair NeuroSciences 2025 and Present Breakthrough Research on Alzheimer’s Disease and Obesity | Biomed Industries, Inc- logo NA-831 for Alzheimer's Disease NA-931 for weight loss Biomed Industries, Inc. CEO to Chair NeuroSciences 2025 and Present Groundbreaking Research on Alzheimer’s, Obesity, and Rett Syndrome Biomed pioneers ground... |
| 03.03.2025 | Biomed Industries, Inc. to Announce Phase 2/3 Results of NA-921 for Treating Rett Syndrome at the IRSF Conference 2025 | Biomed Industries, Inc. Biomed pipeline Biomed Industries, Inc. to Announce Phase 2/3 Results of NA-921 for the Treatment of Rett Syndrome at the IRSF Rett Syndrome Scientific Conference 2025 The Phase 2/3 results of NA-921 shows strong pot... |
| 16.01.2025 | Biomed Industries, Inc. Expands Patent Protection for Novel Combination Therapy Targeting Obesity | Biomed Industries, Inc- logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. Expands Patent Protection for Novel Combination Therapy Targeting Obesity The future of obesity treatment lies in combination therapies. We are conf... |
| 18.12.2024 | Biomed Industries, Inc. to Present Promising Data on NA-931, a Quadruple Receptor Agonist for Obesity and Hypertension | Biomed Industries, Inc- logo NA-931 for weight loss Biomed pipeline Biomed Industries, Inc. to Present Promising Data on NA-931, a Quadruple Receptor Agonist for Obesity and Hypertension at the ICHH 2025 in Tokyo The treatment with the new ... |
| 10.12.2024 | Biomed Industries, Inc. to Present Combination Therapy Phase 2 Protocol of NA-931 and Tirzepatide at ICOCD-2025 | Biomed Industrie, Inc. logo NA-931 for weight loss pipeline Biomed Industries, Inc. will present combination therapy phase 2 clinical protocol of NA-931 and Tirzepatide at ICOCD on January 2–3, 2025, in Seattle, WA By combining the oral NA-... |
| 21.10.2024 | Biomed Industries Presents Phase I Results of its Oral Quadruple Receptor Agonist NA-931 at the 2024 Obesity Conference | Biomed Industries, Inc. logo NA-931 for weight loss pipeline Biomed Industries, Inc. Presents Positive Phase I Results for Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment at Obesity International Conference The phase I results ... |
Show more